Financial Results | Maxcyte 2025 Full Year Revenue USD 33.03 Million Net Loss USD 44.63 Million
Maxcyte(MXCT) posted the Q4 of its 2025 financial results on 3/25/2026, reporting total revenue of USD 33.03 million for the year, down 14.50% from USD 38.63 million year over year, reporting net loss of USD 44.63 million for the year, expanding 8.71% from USD -41.06 million year over year. The EPS is USD -0.42 for the year, compare with USD -0.39 last period.
[Detailed Data]
| Million USD | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Total Revenue | 7.30 | 6.83 | 8.51 | 10.39 |
| Cost of Sales | 1.61 | 1.60 | 1.52 | 1.50 |
| Gross Profit | 5.69 | 5.23 | 6.99 | 8.89 |
| Total Operating Expenses | 15.29 | 17.65 | 19.35 | 19.15 |
| Operating Income | -9.60 | -12.42 | -12.36 | -10.26 |
| Net Income | -9.60 | -12.42 | -12.36 | -10.26 |
| Net Income Attributable to Common Shareholders | -9.60 | -12.42 | -12.36 | -10.26 |
| EPS(USD) | -0.0899 | -0.12 | -0.12 | -0.1 |
[Company Profile]
MaxCyte, Inc., was incorporated on July 31, 1998 under the laws and regulations of the State of Delaware. The company is a leading commercial cell engineering firm providing its proprietary Flow Electroporation technology platform to enable the discovery, development, and commercialization of next-generation cell therapies. Its ExPERT platform supports a range of applications across the cell therapy sector, from research to commercial production.
Comentarios
Aún no hay comentarios